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Abstract
E6 is a small oncoprotein involved in tumorigenesis induced by papillomaviruses (PVs). E6 often
recognises its cellular targets by binding to short motifs presenting the consensus LXXLL. E6
proteins have long resisted structural analysis. We found that Bovine Papillomavirus Type 1
(BPV1) E6 binds the N-terminal LXXLL motif of the cellular protein paxillin with significantly
higher affinity as compared to other E6/peptide interactions. Although recombinant BPV1 E6 was
poorly soluble in the free state, provision of the paxillin LXXLL peptide during BPV1 E6
biosynthesis greatly enhanced the protein’s solubility. Expression of BPV1 E6/LXXLL peptide
complexes was carried out in bacteria in the form of triple fusion constructs comprising, from N-
to C-terminus, the soluble carrier protein MBP (Maltose-Binding-Protein), the LXXLL motif and
the E6 protein. A TEV protease cleavage site was placed either between MBP and LXXLL motif
or between LXXLL motif and E6. These constructs allowed us to produce highly concentrated
samples of BPV1 E6, either covalently fused to the C-terminus of the LXXLL motif (intra-
molecular complex) or non-covalently bound to it (inter-molecular complex). Heteronuclear NMR
measurements were performed and showed that the E6 protein was folded with similar
conformations in both covalent and non-covalent complexes. These data open the way to novel
structural and functional studies of the BPV1 E6 in complex with its preferential target motif.
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INTRODUCTION
Papillomaviruses (PV) are small DNA viruses that infect epithelial tissues and produce
hyperplasias within mammals, birds, and reptiles. Almost 200 PV types have been identified
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[1]. PVs display distinct tropisms for different body sites (skin, mouth and genitalia) as well
as distinct levels of pathogenicity. Although papillomaviruses initially produce benign
hyperplasias, in a subset of virus types termed “high-risk”, these lesions can progress to
cancer. In humans, cervical cancers are caused by infection with high-risk genital Human
Papillomaviruses (HPVs) [2] of which HPV16 is the most common “high-risk” genital type
[3]. Bovine Papillomavirus Type 1 (BPV1) is one of the most extensively studied animal
papillomavirus, serving as a model system for papillomavirus transcription, transformation
and replication [4].
PV tumorogenesis results primarily from the activities of two virally encoded oncoproteins,
E6 and E7. E6 proteins from “high-risk” genital HPVs bind directly to the cellular E3
ubiquitin ligase E6-Associated Protein (E6AP) [5] and then recruits and forms a trimeric
complex with the tumor suppressor p53, leading to ubiquitin–mediated degradation of p53
[6]. “High-risk” genital HPV E6 proteins also target many other cellular proteins to
degradation (reviewed in [7]), including PDZ-containing proteins, which recognise a short
motif at the extreme C-terminus of E6 [8].
HPV16 E6 binds directly to several of its targets proteins (including E6AP [9], E6BP [10],
IRF-3 [11] and possibly p300/CBP [12, 13]) via “charged leucine” motifs, also called
“LXXLL” motifs. These motifs contain the consensus LxxφLsh sequence, where L indicates
conserved leucine residues, φ is an hydrophobic residue (usually a leucine), h is an amino
acid residue with a side chain capable of accepting hydrogen bonds (Asp, Glu, Asn, or Gln),
s represents a small amino acid residue (Gly or Ala) and xx is a dipeptide where one of the
residues is Asp, Asn, Glu or Gln [10, 14]. BPV1 E6 also directly binds the LXXLL motif of
E6AP, as well as LXXLL motifs found on the focal adhesion protein paxillin and possibly
p300 and the AP1 adapter complex [15-17]. This interaction is required for cellular
transformation by BPV1 E6 [17, 18].
Most mammalian PV E6 proteins are cysteine-rich small proteins of about 150 amino acids,
consisting of two zinc-binding domains, E6-N and E6-C [19, 20]. We solved by NMR the
solution structure of a mutant of HPV16 E6-C domain [21]. To date the three-dimensional
structure of any entire E6 protein has not been determined, due to difficulties in its
recombinant production. Attempts to produce the native full-length protein in E. coli have
mainly focussed on E6 from HPV16 [19, 22-25]. Recently, we also explored the behavior of
several E6 proteins of other HPV types, including major “high-risk” genital HPV18, 33, 45,
52, 58, “low-risk” genital HPV11 and high-risk cutaneous HPV5 [26, 27]. None of the HPV
E6 proteins investigated raised samples amenable to structural analysis.
In the present work, we explored the suitability of various constructs of the BPV1 E6 protein
for biophysical and structural analysis. We found that binding of BPV1 E6 to the to the
LXXLL motif of paxillin, in either an inter-molecular complex (non-covalent) or intra-
molecular complex (covalent, obtained by fusion of the LXXLL containing peptide to the N-
terminus of the E6 protein), greatly enhanced the E6 protein’s stability.
MATERIALS AND METHODS
MBP-E6 fusion constructs
Three constructs were generated where the DNA encoding for full-length BPV1 E6 (137,
Genbank CAB 4650) was inserted in the pETM41 vector (kindly provided by G. Stier,
EMBL, Heidelberg). In the first construct, BPV1 E6 was cloned at the C-terminus of 6His-
tagged maltose binding protein (MBP) via a linker sensitive to TEV protease as previously
described [26]. The second construct, referred to as MBP-tevs-LXXLL-E6, consists of the
10 amino acids of the N-terminal E6-binding LXXLL motif of paxillin (residues 1-10) fused
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to the N-terminus of E6 via a short 7 residue linker (detailed sequence: [6HisMBP]-
[MSENLYFQGAMDDLDALLADKESGGSA]-[E6]). In the third construct, named MBP-
LXXLL-tevs-E6 we fused directly the LXXLL motif to the C-terminus of 6his-MBP and
introduced the TEV sensitive linker at the junction between the LXXLL motif and the E6
sequence (detailed sequence: [6HisMBP]-[MDDLDALLADGGSGSNENLYFQGSG]-
[E6]). All clones were verified by DNA sequencing.
GST-peptide constructs
DNA oligomers coding for the negative control GSN-rich peptide (sequence :
GSNSGNGNS), the paxillin (residues 2-10) peptide (sequence : DDLDALLADKE) and the
E6AP (residues 403-417) peptide (sequence: ESSELTLQELLGEER) were cloned into the
NcoI/KpnI sites of the pETM-30 expression vector containing a N-terminal 6HisGST tag
and a TEV protease cleavage site.
Expression and purification procedures
BPV1 E6 fusion constructs were expressed overnight at 15 °C in Escherichia coli
BL21(DE3) cells grown in either LB or M9 medium supplemented with 15N labelled
ammonium sulfate salts. All purification buffers were extensively degassed and equilibrated
with argon. Expression cultures were harvested by centrifugation and resuspended in buffer
A (Tris 50 mM pH 6.8, NaCl 400 mM, and DTT 2 mM) supplemented with 5% glycerol, 2.5
μg/ml DNase I, 2.5 μg/ml RNase I, 1 μg/ml lysozyme and anti-protease cocktail (Roche
Applied Science) at the concentration recommended by the manufacturer. Cells were broken
by sonication on ice and then centrifugated at 38,000 rpm for 1h at 4 °C. The supernatant
was loaded on an affinity amylose resin column (New England Biolabs) equilibrated in
buffer A. After extensive washing, the protein fusion was eluted using buffer A containing
10 mM maltose. Hence, the affinity purified sample was ultracentrifuged overnight at
110,000 g and 4 °C in a SW41 rotor (Beckman). Subsequently, the MBP moiety was
removed by TEV protease digestion carried out at 8 °C for 12 up to 36 hours. In the case of
the 6His-MBP-LXXLL-tevs-E6 TEV protease digestion was performed in the presence of a
four-fold stoichiometric excess of synthetic peptide derived from paxillin (see Results
section for further details). The digested product was concentrated and loaded on a HiLoad
16/60 Superdex 75 gel filtration column (Amersham Biosciences) previously equilibrated in
buffer B (20 mM sodium phosphate buffer (pH 6.8), NaCl 200 mM, and DTT 2 mM).
Protein concentration was estimated by absorption at 280 nm.
GST-peptide fusions for SPR binding experiments (see below) were over-expressed from 20
ml LB cultures of BL21 DE3 Escherichia coli cells for 3 hours at 37 °C. Cells were
harvested and resuspended in 1.5 ml of buffer A supplemented with 5% glycerol, 1% NP-40,
1 μg/ml DNase I, 1 μg/ml Rnase I, 1 μg/ml lysozyme, anti-protease inhibitor cocktail,
broken by sonication on ice in 2.5 ml eppendorf tubes and centrifuged in a microfuge at
maximal speed and at 4 °C for 15 min. Supernatants were thus coupled to the Biacore sensor
surface.
Surface Plasmon Resonance experiments
Surface Plasmon Resonance (SPR) experiments were performed at 25 °C on a BIAcore 2000
instrument (Biacore) equilibrated in buffer B. The experimental set-up followed was
described in a previous publication [28]. Briefly, peptides containing the LXXLL motives of
paxillin and E6AP and a negative control peptide were expressed fused to GST (see above)
and captured onto the Biacore’s surface via a polyclonal anti-GST antibody. The analyte
protein was monomeric BPV1 E6 fused to MBP (MBP-E6) isolated by gel-filtration 24
hours prior to injection and concentrated to a stock concentration below the aggregation
threshold (i.e. 20 μM). We previously demonstrated that the MBP tag does not significantly
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alter binding properties of E6 proteins to their target peptide while permitting the
preservation of the E6 as a soluble monomer and an increase of the SPR signal [29]. The
analyte MBP-E6 protein was therefore injected and the interaction with the captured
peptides monitored. Immediately after synthetic peptide containing the LXXLL motif from
either E6AP or paxillin (depending on whether GST-E6AP or GST-paxillin was
immobilized on the surface) was injected at a concentration of 20 μM during the analyte’s
dissociation phase, thus avoiding a regeneration step. The negative control peptide
sensorgram was used to correct for non-specific binding whereas buffer effects were
corrected by subtracting buffer injection sensorgrams. All data were interpreted using the
BiaEvaluation 3.2 software (Biacore). Kinetic data were interpreted by global fit using a
simple Langmuir interaction model. The kinetic parameters reported were obtained from fits
with χ2 values smaller than 4% of the globally fitted Rmax values.
Synthetic peptides
The paxillin and E6AP derived synthetic peptide presented the following sequences:
EFTMDDLDALLADKE and ESSELTLQELLGEER.
NMR spectroscopy
1H,15N HSQC spectra were acquired on a Bruker DRX600 spectrometer equipped with a z-
gradient triple-resonance cryoprobe at 296 K. Samples were buffer exchanged against 20
mM sodium phosphate buffer (pH 6.8), 200 mM NaCl, 2 mM DTT, 10% D2O.
Mass spectrometry
Samples for MALDI-TOF mass spectrometry were recovered from 15% SDS-PAGE gels
and subjected to trypsin digestion according to standard protocols. Measurements were
performed of a Reflex IV sperctrometer (Bruker, Germany). Samples for electronspray
ionization mass spectrometry were buffer exchanged against 100 mM ammonium acetate at
pH 7.0. Native spectra were recorded at a sample concentration of 12 μM. For the
measurements in denaturing conditions the sample was diluted in a 1:1 water/acetonitrile (v/
v) mixture acidified with 1% formic acid to achieve a concentration of 5 μM. Measurements
were performed on an MicOTOF mass spectrometer (Bruker, Germany).
RESULTS
Domain architecture and stability of BPV1 E6
Sequence alignement of BPV1 E6 versus E6 proteins from a subset of HPV species (Fig.
1A) shows that zinc-binding cystein residues as well as most of key buried hydrophobic
positions are conserved across human and bovine PV species. These observations suggest
that BPV1 E6 contains two zinc-binding domains with folds similar to the HPV
counterparts.
We therefore applied to BPV1 E6 the same expression and purification protocols developed
for the other HPV E6 proteins [26]. The wild-type sequence of full-length BPV1 E6 was
fused to the C-terminus of Maltose Binding Protein (MBP) via a linker sensitive to TEV
protease, over-expressed and affinity purified on amylose resin. Overnight
ultracentrifugation to clear soluble MBP-E6 aggregates led to a significant loss of material
in the supernatant (Fig. 1B, lanes 2 and 3). The cleared sample was then subject to TEV
protease cleavage. The identity of the BPV1 E6 band generated after TEV digestion and
migrating at 16 kDa (Fig. 1B, lane 4) was confirmed by MALDI-TOF mass spectrometry
analysis (Table S1, Supplementary data). The digested sample was subsequently loaded on a
gel-filtration column (Fig. 1C). We could only recover low amounts of protein at the elution
volume expected for monomeric BPV1 E6 separated from the MBP tag. In addition gel
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filtrated E6 could not even stand further concentration due to precipitation onto the
concentrator’s membrane.
We have previously observed that the MBP tag slows down the formation of higher-order
multimeric species of E6 proteins, including BPV1 E6 [27]. Indeed monomeric MBP-BPV1
E6 fusion previously purified by gel filtration chromatography could be concentrated up to
20 μM without undergoing precipitation (data not shown).
BPV1 E6 binds with high-affinity to the LXXLL motif of paxillin
The BPV1 E6 protein has been shown to bind to several peptides bearing the LXXLL
consensus motif [17, 18]. We investigated the binding of BPV1 E6 to two distinct peptides
containing respectively the LXXLL motif of E6AP and the N-terminal LXXLL motif of
paxillin by SPR (Biacore). Freshly purified monomeric MBP-E6 was injected at varying
concentrations on sensor surfaces capturing the GST-peptide fusions and the interactions
monitored.
The sensorgrams shown in Fig. 2 denote a remarkably slow dissociation phase for the E6/
paxillin interaction as compared to E6/E6AP. Kinetic analysis using a simple bimolecular
Langmuir interaction model yielded koff rate values of 0.2 and 1.7 × 10−3 M−1 s−1 for the
E6AP and paxillin peptides respectively. The equilibrium (KD), values estimated from the
koff/kon ratios are 1.3 μM and 35.1 nM (Table 1). Therefore, whereas the affinity of the
BPV1 E6 / E6AP interaction approximates that of HPV16 E6 / E6AP (4 μM) [29], the
affinity of BPV1 E6 for the paxillin peptide is significantly stronger.
Strategies for the purification of complexes of BPV1 E6 bound to N-terminal LXXLL motif
of paxillin
The strong affinity of BPV1 E6 for the N-terminal LXXLL motif of paxillin suggested us
the possibility that this interaction might stabilize E6 in a conformation that is not any more
prone to self-association. Based on this assumption we have designed a number of
expression and purification strategies for the production of samples of BPV1 E6/paxillin
complexes.
Initially we have tested a number of co-expression and co-purification protocols. Co-
purification of GST-paxillin peptide and MBP-BPV1 E6 fusion expressed in separate
bacterial cultures was attempted on either amylose (MBP-binding) or gluthatione (GST-
binding) resins. This approach yielded very little amounts of complex, most probably
because MBP-E6 aggregates pre-formed upon bacterial expression were not proficient for
binding to the peptide (data not shown). A related approach, consisting of adding an excess
of synthetic paxillin peptide to MBP-E6 expressions during cell lysis was also unsuccessful
(data not shown). Finally, co-expression within the same bacterial cell of GST-paxillin
peptide and untagged E6, both constructs being expressed by plasmids bearing different
replication origins [30], led to co-purification of BPV1 E6 and GST-paxillin peptide, albeit
at levels too modest for biophysical and structural studies (data not shown).
We therefore tried to stabilize BPV1 E6 by expressing the paxillin LXXLL motif and the E6
protein “in cis” on the same fusion construct. Two alternative constructs were generated.
The first fusion protein (MBP-tevs-LXXLL-E6) was constructed as follows: [6HisMBP]-
[TEV site]-[paxillin peptide]-[E6] (Fig. 3, left panel). The MBP-tevs-LXXLL-E6 fusion
protein was expressed and purified exactly as described above for MBP-E6. The affinity
purification on amylose resin raised amounts of soluble MBP-tevs-LXXLL-E6 fusion
equivalent to the amounts of soluble MBP-E6 previously obtained. However, the
ultracentrifugation step indicated that the MBP-tevs-LXXLL-E6 preparations contained very
little amounts of soluble aggregates as compared to MBP-E6 preparations (Fig. 4A, lanes 2
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and 3). TEV digestion of the MBP-tevs-LXXLL-E6 fusion was unusually slow (up to 36
hours), suggesting that the conformation of the LXXLL-E6 construct hindered accessibility
to the proteolytic site. The identity of the LXXLL-E6 band (Fig. 4A, lanes 3) was confirmed
by MALDI-TOF analysis (Table S2, Supplementary data). By contrast to what was
previously observed for the MBP-E6 construct, the LXXLL-E6 moiety released by TEV
proteolysis did not undergo precipitation neither during the proteolysis reaction nor during
the subsequent concentration step. Gel filtration raised large amounts of monomeric
LXXLL-E6 (Fig. 4B). In addition LXXLL-E6 samples could be concentrated up to 300 μM
without undergoing any detectable aggregation.
To extend this approach, a second fusion protein (MBP-LXXLL-tevs-E6) was constructed
as follows: [6HisMBP]-[paxillin peptide]- [TEV site]-[E6] (Fig. 3 right panel). This fusion
protein was highly expressed as a soluble form. Like for the MBP-tevs-LXXLL-E6
construct, affinity purified MBP-LXXLL-tevs-E6 contained only minor amounts of
aggregated material when submitted to overnight ultracentrifugation (Fig. 4C, lanes 2 and
3). The MBP-LXXLL-tevs-E6 preparation was further processed as the MBP-tevs-LXXLL-
E6 construct, with the following modification: TEV digestion was performed in the presence
of a four-fold stoichiometric excess of synthetic LXXLL paxillin peptide, to allow the
released E6 moieties to be displaced from the MBP-fused LXXLL peptides to the small
synthetic peptides. The E6/peptide complex was then separated from MBP-paxillin peptide
and TEV by gel-filtration, eluting at the volume expected for a monomeric complex (Fig.
4D). The gel-filtrated sample could be concentrated up to 300 μM just like the covalent
LXXLL-E6 fusion described before. To further verify the integrity of the E6 and LXXLL
peptide in the non-covalent complex, we performed electronspray mass spectrometry
analysis in both denaturing and native conditions. In denaturing conditions we identified two
species of 1724.8 and 16051.4 Da, corresponding respectively to the LXXLL peptide
(predicted molecular weight 1725.8 Da) and BPV1 E6 (predicted molecular weight 16051.6
Da). When the analysis was performed in native conditions we obtained a single species of
17904.3 Da, which corresponds to the sum of the molecular weights of the LXXLL peptide,
BPV1 E6 and the two zinc atoms (predicted molecular weight of the complex: 17911.2 Da)
(Table 2).
We also designed a GST-LXXLL-tevs-E6 construct that we attempted to purify in a similar
manner. However, the solubility of this construct was poor as compared to that of the MBP-
LXXLL-tevs-E6 (data not shown). This suggests that MBP acts in synergy with the LXXLL
peptide to increase the soluble amounts of BPV1 E6 protein during biosynthesis in bacteria.
NMR analysis of BPV1 E6/paxillin complexes
The expression of both the MBP-tevs-LXXLL-E6 and MBP-LXXLL-tevs-E6 fusion
constructs were reproduced in appropriate minimal M9 media, giving rise to 15N-labeled
samples that were subsequently purified according to the protocols described above and
concentrated up to 300 μM. The 1H, 15N-HSQC spectrum of the covalent LXXLL-E6 fusion
complex (Fig. 5A) displays and the chemical shift dispersion typical for a folded protein.
Approximately 147 amide peaks can be counted in the HSQC spectrum. This number is
close to that predicted from the sequence of the LXXLL-E6 construct (consisting of 155
amino acids of which 6 are proline residues). The 1H, 15N-HSQC spectrum of the non-
covalent complex of BPV1 E6 with non-labelled synthetic LXXLL peptide (E6/LXXLL) is
also typical for a folded protein (Fig. 5B). The number of amide peaks counted in the
spectrum is 130, which is close to the number of amide resonances in the 15N labelled BPV1
E6 counterpart (140 residues of which 6 are prolines) of the complex. Interestingly, signal
line-width in the latter spectrum appears more homogeneous when compared to that of the
first spectrum. This suggests that the covalent peptide fusion to the N-teminus of BPV1 E6
might introduce some constraints to complex dynamics and stability. Superimposition of the
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two spectra (Fig. 5C) indicates that the majority of amide signals in the better dispersed
regions of the spectrum have very similar chemical shift values, suggesting that the
conformations of E6 in the covalent and non covalent complexes are very similar.
DISCUSSION
Papillomavirus E6 proteins are notoriously difficult to express and purify. Unfused E6
proteins form insoluble aggregates upon bacterial overexpression. Usual purification tags
such as the 6His-tag or the Gluthatione-S-Transferase (GST) generate no or little
solubilization of E6. By contrast, fusion to the Maltose-Binding Protein (MBP) is
particularly efficient in solubilising E6 proteins. However, a large fraction of the soluble
MBP-E6 proteins may exist as soluble aggregates. We have previously developed various
assays to detect these soluble aggregates and used ultracentrifugation approaches to
eliminate them [23, 26, 31]. However, monomeric E6 proteins obtained by these procedures
generally remain prone to self-association at high concentration, hindering their biophysical
and structural analysis [27].
The BPV1 E6 protein studied in this work generally behaves in a manner comparable to that
of the HPV E6 proteins studied to date. GST-BPV1 E6 fusions are poorly soluble (data not
shown) whereas MBP-BPV1 E6 fusions are soluble but largely under the form of soluble
aggregates and/or small size oligomers [27]. These aggregates can be cleared by
ultracentrifugation, allowing one to isolate, after removal of MBP by proteolysis, only
diluted amounts of monomeric E6 that cannot stand further concentration required for
biophysical analysis.
To turn around this problem, we have searched for means of improving the solubility of
BPV1 E6. Previous studies had shown that a construct of BPV1 E6 fused to the C-terminus
of the same paxillin-derived LXXLL peptide used in the present study was inactivated in
vivo for biological functions requiring interactions with partners possessing a LXXLL E6-
binding motif. This suggested that the fused peptide was efficiently blocking the LXXLL-
binding site of BPV1 E6 [18]. SPR measurements showed that BPV1 E6 binds to the
paxillin LXXLL peptide with high affinity and slow dissociation rate kinetics. Given its
stability, we reasoned that the protein/peptide complex may persists through the purification
steps and ensure the stabilization of the E6 protein at high concentrations. Indeed the
conserved leucine residues of the LXXLL motif are likely to interact with a hydrophobic
patch exposed on the surface of E6, which may promote aggregation of the unbound protein.
We tested several alternative strategies. Approaches based on co-expression and co-
purification of BPV1 E6 and the cognate peptide were unsuccessful or yielded insufficient
amounts of complexes. By contrast, approaches based on “in cis” expression of MBP,
peptide and E6, in the form of triple fusion, turned out to be remarkably successful. Two
alternative strategies were used to express and purify samples of BPV1 E6/paxillin
complexes. One strategy, based on the MBP-tevs-LXXLL-E6 construct, led to a covalent
(intra-molecular) LXXLL-E6 fusion contruct, which proved soluble at high concentrations
and amenable to biophysical analysis by NMR. The second strategy, based on the MBP-
LXXLL-tevs-E6 construct, allowed us to obtain samples of a non-covalent (inter-molecular)
E6/LXXLL complex, which was equally soluble at high concentrations and also amenable to
NMR studies. This latter approach has the advantage of allowing for subunit specific
labelling, thus reducing the complexity of NMR spectra. The success of the triple fusion
approach indicates that both peptidic ligand and MBP tag are required during biosynthesis
for the solubilization of BPV1 E6.
In our previous work, we have shown that mutagenesis of non-conserved cysteins to the
isosteric non-oxidable residue serine notably increased the solubility of recombinant HPV16
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E6 protein [23]. We have tried to reproduce this approach by producing various mutants of
BPV1 E6 in which all or some of the non-conserved cysteins were mutated to serines. None
of these mutants displayed improved solubility as compared to the wild-type BPV1 E6
protein (data not shown). In parallel, we also generated constructs where the LXXLL motif
of E6AP was fused to the N-terminus of HPV16 E6 (MBP-tevs-LXXLL-HPV16E6) via
linkers of different sizes. None of these constructs led to a significant improvement of
HPV16 E6 solubility (data not shown), a result that might be related to the weaker affinity
of this interaction.
Therefore, a similar problem (aggregation of protein upon expression and concentration)
occurring for two proteins belonging to the same family (papillomavirus E6 proteins) had to
be treated by two different approaches (cystein mutagenesis and stabilisation by peptidic
ligand for HPV E6 and BPV E6 respectively). This shows that, even for closely related
proteins, there are no definite standard recipes for enhancing sample solubility.
Both BPV1 E6 and HPV16 E6 both bind to peptides possessing the consensus LXXLL [18].
We have found here that a LXXLL peptide from paxillin forms with BPV1 E6 a tight
complex (KD=35 nM). On the other hand, the interactions of BPV1 E6 and other “high-risk”
genital HPV E6 proteins with the LXXLL peptide of E6AP have 30-to-1000-fold lower
equilibrium binding affinity constants (KD=1-30 μM) [29]. These observations on the
affinities of E6 proteins towards different LXXLL containing peptides may have functional
implications. The E6/paxillin complex may exist permanently in BPV-infected cells,
whereas the E6/E6AP complex may be more transient, allowing for the formation of
alternative complexes.
To summarize, we have shown that, like Human Papillomavirus E6, the E6 protein of
Bovine Papillomavirus is prone to aggregation, hindering its biophysical analysis. However,
the protein becomes highly soluble and amenable to biophysical analysis provided that it is
complexed, covalently or non-covalently, with its main peptidic ligand. This finding opens
the way to novel structural and functional studies of this potent mammalian oncoprotein. In
addition, the original approaches that we have developed in this work might be applicable to
other cases of proteins that are only stable and/or soluble in the presence of a peptidic
partner.
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NMR nuclear magnetic resonance spectroscopy.
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(A) Alignment of E6 sequences (upper half E6-N and lower half E6-C) from the BPV1 and
several HPV species. Residues are numbered as in the shorter transcript of HPV 16 E6 (151
residues). Positions exhibiting conserved physicochemical characteristics are colored as
follows: magenta, hydrophobic (W, F, Y, L, I, V, M); green, basic (K, R, H); red, acidic (E,
D); orange, polar (Q, N, T, S); brown, cystein (C); cyan, small (G, A, P). (B) 15% SDS-
PAGE gel showing the different purifications steps of BPV1 E6. Affinity-purified MBP-E6
was cleared from soluble aggregates by ultracentrifugation and digested using TEV
protease. Subsequently, the sample was concentrated and injected on a HighLoad
Superdex75 16/60 column. Lane 1: total cell lysate; lane 2: eluate from amylose resin before
overnight ultracentrifugation; lane 3: eluate from amylose resin after overnight
ultracentrifugation; lane 4: TEV protease digest. (C) Gel filtration after separation from the
MBP by TEV digestion. Peaks corresponding to the MBP and E6 proteins are indicated.
Note that very small amounts of monomeric E6 are recovered after gel filtration.
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Biacore datasets used for kinetic analysis of the interactions of MBP-BPV1 E6 with peptides
containing (A) the LXXLL motif of E6AP and (B) the N-terminal LXXLL motif of paxillin.
Gray lines represent SPR sensorgrams obtained by injecting analyte MBP-E6 on surfaces
capturing 60 (A) and 30 (B) RUs of GST-peptide ligand. The concentration of analyte is
indicated on the right hand side of each sensorgram. Black lines are the global fits of the
sensorgrams to a simple bimolecular Langmuir model. The ratio of the globally fit Rmax
(Rmaxglobal) over the theoretical Rmax (Rmaxtheoretical -estimated from the amount of
fusion peptide captured-) Rmaxglobal/Rmaxtheoretical was 0.9 and 0.6 for the GST-paxillin
and GST-E6AP ligands. Kinetic parameters are reported in Table 1.
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Purification scheme for the MBP-tevs-LXXLL-E6 construct (left) and the MBP-LXXLL-
tevs-E6 construct (right). Both constructs stabilise the BPV1 E6 protein during expression
by allowing it to form a complex in cis with its cognate LXXLL motif peptide. TEV
digestion is carried out for both constructs after the first affinity purification step. In the case
of the MBP-tevs-LXXLL-E6 construct, this leads to the isolation of pure covalent LXXLL-
E6 complex after gel filtration. On the other hand, TEV proteolysis of the MBP-LXXLL-
tevs-E6 construct is performed in the presence of a 4-fold excess of LXXLL synthetic
peptide, which binds to the E6 moiety, allowing the displacement of the MBP-LXXLL
fusion and leading to isolation of the non-covalent E6/LXXLL complex after gel filtration.
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Purification of the construct of MBP-tevs-LXXLL-E6 (A-B) and MBP -LXXLL-tevs-E6
(C-D) constructs. (A and C) 15% SDS-PAGE gels for the two purifications. Lane 1: total
cell lysate; lane 2: eluate from amylose resin before overnight ultracentrifugation; lane 3:
eluate from amylose resin before overnight ultracentrifugation; lane 4: TEV protease digest;
lane 5: pooled gel-filtration fractions at the elution volume expected for the E6/paxillin
complex. (B and D) Gel filtration profiles of LXXLL-E6 and E6/LXXLL samples after
separation from the MBP. Peaks corresponding to MBP-tevs or MBP-LXXLL-tevs and to
E6/paxillin complexes are indicated. See also legend of Fig. 1.
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1H-15N HSQC spectra of (A) 15N labelled LXXLL-E6 fusion (covalent) and of (B) 15N
labelled E6 bound to unlabelled LXXLL peptide (non-covalent). Spectra were acquired with
32 scans at 296 K. (C) Overlay of spectra shown in A (black) and in B (red).
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Table 1
Kinetic parameters derived from Biacore sensorgrams shown in Figure 2.
kon (M−1 s−1) koff (s−1) koff/kon (M)
BPV1 E6/E6AP 1.5 ×105 0.2 1.3 × 10−6
BPV1 E6/paxillin 5.0 × 104 1.7 × 10−3 3.5 × 10−8
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Table 2
Molecular weights of the non-covalent BPV1 E6/paxillin complex and its components as derived from both







predicted 16051.6 1725.8 17903.2
denaturing mass-spec 16051.4 1724.8 -
native mass-spec - - 17904.3
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